国药现代：维生素B6注射液规格获批一致性评价

Core Viewpoint - The approval of the new specification for Vitamin B6 injection by the National Medical Products Administration is expected to facilitate market expansion and sales for the company, although it will have a limited impact on current operating performance [1] Company Summary - The company, under its wholly-owned subsidiary Guoyao Rongsheng, received a notification for the approval of a supplementary application for Vitamin B6 injection, allowing for a new specification of 1ml:0.1g [1] - The cumulative R&D investment for this project has reached 4.0885 million yuan [1] Industry Summary - The Vitamin B6 injection is primarily used for the prevention and treatment of Vitamin B6 deficiency and other related indications [1] - The projected sales revenue for this drug in public medical institutions nationwide is approximately 304 million yuan for the year 2024 [1]